Review

Intestinal Permeability Markers in Depression – A Narrative Review

Anca Cristina Bibolar , Bianca D. Crecan-Suciu * , Ramona Liana Paunescu , Vlad Ionut Nechita , Olivia Verisezan Rosu , Ioana Valentina Micluția

Posted Date: 19 August 2025

doi: 10.20944/preprints202508.1326.v1

Keywords: intestinal permeability; depression; zonulin; lipopolysaccharides; biomarkers

 doi:10.20944/preprints202508.1326.v1

Review

Intestinal Permeability Markers in Depression—A Narrative Review

Anca C. Bibolar[1], Bianca D. Crecan-Suciu[1] *, Ramona L. Păunescu[1], Vlad I. Nechita [2], Olivia Verisezan-Roșu [3] and Ioana V. Micluția[1]

[1] Department of Neurosciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, 43 Victor Babeș Street, Cluj-Napoca 400012, Romania

[2] Department of Medical Informatics and Biostatistics, "Iuliu Haţieganu" University of Medicine and Pharmacy, 6 Pasteur Street, Cluj-Napoca 400349, Romania

[3] RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania

* Correspondence: suciu.bianca@umfcluj.ro

Abstract

The intestinal barrier has recently gained attention as a contributor to the pathophysiology of depression. This narrative review examines the current literature on blood-based markers of intestinal permeability in patients with depression. A structured search of PubMed and EMBASE was performed. Both recent and older studies were included to capture key mechanisms and theoretical foundations. We focused on zonulin, intestinal fatty acid-binding protein (I-FABP), lipopolysaccharides (LPS), LPS-binding protein (LBP), and soluble CD14 (sCD14). While several studies report altered intestinal permeability markers in individuals with depression, results remain inconsistent. Factors such as small sample sizes and variability in measurement procedures complicate interpretation. In some cases, altered biomarker levels were associated with disease severity or response to antidepressant treatment, suggesting a potential role in patient stratification. However, current evidence does not support their routine use in clinical settings. Further research is needed to clarify their specificity and predictive value in psychiatric populations. Once validated, these markers may help identify inflammation-related depression subtypes and guide more precise treatment strategies.

Keywords: intestinal permeability; depression; zonulin; lipopolysaccharides (LPS); biomarkers

1. Introduction

Depression is a widespread mental health disorder marked by persistent emotional and cognitive, as well as physiological disturbances [1]. While antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and psychotherapy are the standard of care, roughly half of major depressive disorder (MDD) patients are poorly responsive [2]. New insights into neurotransmitter imbalance, immune system activation and neuroinflammation have resulted in novel therapies over the past years. However, the lack of established neuroimaging, neuroendocrine, inflammatory, genetic or metabolic markers complicates diagnosis and treatment. The interest for gut dysbiosis and gut permeability in depression is increasingly relevant. However, standardized dysbiosis-related biomarkers also remain unestablished.

Intestinal permeability biomarkers might aid in the evaluation of treatment-resistant depression, help stratify individuals based on gut-related inflammation, promote earlier diagnosis and monitor treatment response. Given the emerging role of gut integrity in mental health, understanding the functional and structural basics of the intestinal barrier (IB) becomes essential. The human body is constantly exposed to various microorganisms and toxins. The IB captures nutrients and retains pathogenic microbes, chemicals, toxins or allergens. Structured in multiple layers, it acts as a physical

 doi:10.20944/preprints202508.1326.v1

and functional shield [3]. Tight junctions (zonula occludens - ZO), adherens junctions (zonula adherens), and desmosomes, reinforce the barrier at the epithelial level [4]. Compromising factors include psychological stress, dysbiosis, bacterial, parasitic or fungal infections, strenuous exercise, heat stress, alcohol, pesticides and antibiotics [5]. The integrity of the IB is often quantified by measuring intestinal permeability.

There is a scientific consensus regarding IB dysfunction in conditions where epithelial damage and local inflammation are evident, such as celiac disease, Crohn's disease, and NSAID-induced ulceration. In these disorders, increased intestinal permeability is a well-established feature, often accompanied by structural abnormalities of the epithelial lining. The term "leaky gut", while popularized in literature, represents a simplified description of this complex process. More recently, intestinal permeability has been studied in cases where overt inflammation or macroscopic damage may be absent. This condition is now associated with a wide range of disorders, including obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, cardiovascular diseases, type 1 diabetes, and various autoimmune conditions [6]. Studies also found subtle IB dysfunction in neuropsychiatric illnesses. Evidence indicates that both Parkinson's disease (PD) and Alzheimer's disease (AD) are associated with gut dysbiosis and increased intestinal permeability, suggesting a potential role of IB dysfunction in the pathophysiology of neurodegenerative disorders [7,8,9]. By simulating increased gut permeability through the administration of endotoxins, Behairi et al. (2016) created a mouse model characterized by memory impairment, increased systemic nitric oxide (NO) production, upregulated Aβ 1-42 expression in the brain, and neuronal degeneration resembling Alzheimer's disease (AD) [10]. Autism and schizophrenia were also linked to "leaky gut" syndrome [11,12]. Intestinal permeability, as a relevant factor in depression, complements findings in other neuropsychiatric conditions and proposes a shared pathophysiological mechanism that involves gut-brain axis (GBA) dysfunction. Modified levels of gut permeability markers in these conditions could suggest that milder, potentially subclinical, forms of IB dysfunction are sufficient to drive systemic immune activation, contributing to psychological distress. Increased intestinal permeability enables the migration of bacterial endotoxins such as lipopolysaccharides (LPS) into the systemic circulation. This leads to immune response activation, with the release of pro-inflammatory cytokines and systemic inflammation, alongside BBB disruption and neuroinflammation [13,14,15]. The result is an impact on brain function via HPA axis stimulation, increased oxidative and nitrosative stress (O&NS) and microglial activation [16,17,18]. Moreover, LPS modify neurotransmitter balance, reducing 5-HT production 19. The involvement of multiple physiological mechanisms underscores the potential relevance of intestinal permeability beyond the traditional boundaries of gastrointestinal medicine. This narrative review aims to synthesize current evidence on the link between IB dysfunction and depression. The focus is on biomarkers of intestinal permeability, in order to highlight potential pathophysiological mechanisms and their clinical relevance.

2. Materials and Methods

This narrative review is based on a structured search of the PubMed and Embase databases, aiming to identify studies published from 2015 to 2025 that examined the association between depression and blood-based markers of intestinal permeability. The search focused on key biomarkers including zonulin, intestinal fatty acid-binding protein (I-FABP), lipopolysaccharides (LPS), LPS-binding protein (LBP), and soluble CD14 (sCD14), which reflect distinct mechanisms of IB dysfunction. Search terms included the following: "depression", "intestinal permeability", "intestinal barrier", "biomarkers", "zonulin", "intestinal fatty acid binding protein", "I-FABP", "lipopolysaccharide", "LPS", "endotoxins", "sCD14", "lipopolysaccharide binding protein" and "LBP".

This review considered only English-language studies. Both clinical and relevant preclinical studies were included. Studies lacking relevance to intestinal permeability markers were excluded. Screening was conducted independently by two reviewers, with any discrepancies settled through

 doi:10.20944/preprints202508.1326.v1

discussion. Additional articles were identified through manual reference checking and studies older that 10 years were retained when conceptually or mechanistically informative. No formal bias assessment was performed. However, emphasis was placed on methodological robustness and control for key confounders. During manuscript preparation, the authors used ChatGPT-4 (OpenAI, 2025) to provide partial support in enhancing language clarity and for limited assistance with the formatting of Table 1. All outputs were carefully reviewed and edited by the authors, who assume full responsibility for the final content.

An overview of the main intestinal permeability biomarkers identified is provided in Table 1.

Table 1. Blood-Based Markers of Intestinal Permeability and Their Clinical Significance in the Context of Depression.

Marker.	Role	What Modified Levels Indicate
Zonulin	Modulates tight junctions between intestinal cells	Increased intestinal permeability
I-FABP	Released upon intestinal epithelial cell injury	Enterocyte damage
LPS	Bacterial endotoxin from Gram-negative bacteria	Microbial translocation
LBP	Binds LPS and facilitates immune recognition	Increased LPS exposure
sCD14	Soluble receptor for LPS signaling	Immune activation

Abbreviations: I-FABP = Intestinal Fatty Acid Binding Protein; LPS = Lipopolysaccharides; LBP = LPS-Binding Protein; sCD14 = Soluble Cluster of Differentiation 14.

3. Overview of Intestinal Permeability Markers

Methods for assessing intestinal permeability have evolved over time. Several techniques exist, including the administration of monosaccharides (e.g. mannitol), disaccharides (e.g. lactulose and sucralose), polyethylene glycol (PEG) 400 and 51 Cr-EDTA, with the subsequent urinary measurement of the tracer molecules. These well-established tests are considered accurate but time-consuming, unstandardized, and constrained by uncertain reference values. Additionally, in vitro measurements of intestinal biopsies, as well as endoscopic measurements, are also available [19]. Biomarkers commonly used to assess intestinal permeability include albumin, calprotectin, and zonulin, which are measured in stool samples, as well as the blood-based biomarkers I-FABP, LPS, LBP, sCD14 and zonulin [20,21]. Their reliability is subject to debate, as studies do not yet recognize these as official markers. The blood-based biomarkers are easily dosed due to the procedure's minimally invasive nature, making them more practical for clinical and research applications. Here, we discuss their limits and potential contributions in the assessment of IB dysfunction in depression.

3.1. Zonulin

Zonulin is the only known human protein capable of reversibly regulating intestinal permeability by altering tight junctions. It can be measured in blood, stool or intestinal tissue samples, and is considered one of the most reliable serum markers for "leaky gut syndrome". In its intact single-chain form, it operates by activating the epidermal growth factor receptor (EGFR) through proteinase-activated receptor 2 (PAR2) [22]. Zonulin was identified in the year 2000 by the research group of Fasano as the human counterpart of the zonula occludens toxin elaborated by *Vibrio cholerae*, which reversibly induces tight junction disassembly [23]. Later, Tripathi et al. characterized zonulin as pre-haptoglobin 2, an inactive precursor 25. The protein has a molecular weight of 47 kDa and the two most powerful triggers for its release are gluten and bacteria present in the intestine 26,[24]. This indicates that zonulin could act as a mechanistic link between changes in the gut microbiota and IB function. Several gram-negative bacteria (e.g. *Escherichia coli, Prevotella, Pseudomonas, Salmonella*)

 doi:10.20944/preprints202508.1326.v1

were linked to increased intestinal zonulin release and gut permeability. In contrast, certain Gram-positive bacteria (e.g. *Bifidobacterium*, *Lactobacillus*), considered protective of the IB integrity, were associated with lower zonulin levels [25]. Zonulin dysregulation results in the passage of environmental and bacterial antigens. This can precipitate the pathogenesis of several autoimmune disorders such as coeliac disease, in relation to which it was first identified. The observation of increased zonulin expression in the intestinal tissue during the acute phase of the disease, when the tight junctions are opened, proposed a causal role of this endogenous mediator 26. The median value of zonulin is 34 ng/mL (± 14 ng/mL) in healthy individuals [26].

3.2. I-FABP/ FABP2

Fatty acid-binding protein (FABP) was first identified over 50 years ago as a cytoplasmic molecule that binds long chain fatty acids, modulating their absorption [27]. Following the initial discovery, FAPB is now recognized as part of a family of nine proteins that weigh 14–15 kDa and are 126–134 amino acids in length. They are preferentially expressed in tissues where active lipid metabolism occurs. FABPs are named after their first isolation tissue [28]. The family includes liver (L-FABP), intestine (I-FABP), heart (H-FABP), adipose tissue (A-FABP), skin (E-FABP), ileum (Il-FABP), brain (B-FABP), myelin (M-FABP), and testis (T-FABP) proteins. FABPs are not uniquely specific to a particular cell type, and multiple FABP isoforms are expressed in most tissues. As a result of being the second classified isoform, I-FABP is also known as FABP2. It is expressed in the epithelium of the intestine throughout, most abundantly in the distal segment, but also in the liver [29]. Following enterocyte injury, I-FABP is released into circulation, its elevated levels serving as an indicator of intestinal epithelial damage [30]. Thus, I-FABP appears to be a possible serum biomarker for conditions associated with disruption in the IB integrity. Both I-FABP and L-FABP plasma levels were increased in intestinal diseases. In hepatocellular injury alone, only L-FABP was elevated [31]. Serum I-FABP concentrations in healthy subjects are reported to be low [32]. The threshold value for I-FAPB is generally set at 2 ng/mL [33].

3.3. LPS

An important consequence of IB dysfunction is the increased translocation of LPS to the systemic circulation. LPS are present on the surface of most Gram-negative bacteria and the host immune system responds drastically upon their detection. Thus, LPS are considered PAMPs, or pathogen-associated molecular patterns [34,35]. LPS play a crucial role in maintaining membrane integrity and facilitating bacterial interactions with external surfaces [36]. Their structural domains include lipid A, a hydrophobic anchor which aids in the stability of the outer membrane, the O-antigen, and the core oligosaccharide 37. Westphal et al. established in the 1950s a hot phenol/water method for purifying LPS, which remains a standard today. Their research demonstrated that lipid A is responsible for the toxic effects of LPS [37,38]. For more than a century, endotoxins have been deliberately administered to humans for therapeutic purposes, the assessment of anti-inflammatory agents, and the investigation of fundamental aspects of endotoxin biology 41. LPS administration results in a depression-like model in rodents that has been widely used to clarify inflammation-related depression mechanisms and treatment effects 17. LPS stimulate monocytes and macrophages, with the consecutive release of inflammatory cytokines (e.g. IL-1, IL-6, TNF-α) and activation of mediators through signal amplification pathways 16. Within an hour of intravenous LPS administration, two consistent physiological responses are present: fever and a rise in heart rate. Other symptoms, with variation between subjects, include chills, headache, muscle aches, nausea or photophobia. High LPS levels in the bloodstream increases the risk of multisystem organ failure and septic shock. Symptom resolution occurs in approximately 6 to 8 hours. A typical stress response follows the injection of endotoxin, marked by an early ACTH surge and followed by a gradual cortisol rise over 3–4 hours. Catecholamines (epinephrine and norepinephrine) peak within 1–2 hours and decline over the next 4–6 hours [39]. In addition to the systemic inflammatory response, LPS promote microglial activation and the chronic release of pro-inflammatory cytokines in the brain, generating

 doi:10.20944/preprints202508.1326.v1

neuroinflammation 17. One of the most extensively investigated cytokines in this context is TNF-α, with increased levels in the hippocampus and frontal cortex at day 7 and onward following LPS administration. Behavioral assessments identified a persistent cognitive deficit, with severe impairments in responsiveness to the environment that may relate to diminished motivation or attentional dysfunctions [40]. Patients with depression also showed increased IgM and IgA responses to LPS, linked to enhanced immune-inflammatory activity and oxidative and nitrosative stress (O&NS) pathways 21. Moreover, LPS increase blood-brain barrier (BBB) permeability. Upon examining samples from HIV-infected individuals, elevated plasma LPS, BBB disruption and neuroinflammation were identified. Cerebrospinal fluid (CSF) LPS were found undetectable in all samples. Plasma LPS levels correlated with inflammatory markers as well as with BBB permeability in HIV-infected subjects. These findings indicate that microbial translocation contributes to neuroinflammation and BBB disruption without direct entry into the central nervous system [41]. Thus, LPS can be considered potential biomarkers for mental disorders due to their role in triggering systemic inflammation and neuroinflammatory responses. Indicating bacterial translocation, LPS should not be significantly present in the blood in the case of an intact IB.

3.4. LBP and sCD14

Host response mechanisms to Gram-negative bacterial infections rely mainly on LPS recognition. The prevailing dogma until 1990 was that LPS activated immune cells via a non-specific mechanism [42]. This principle was finally disproved with the identification of LBP, first characterized by Tobias et al. (1986) as an acute-phase protein, part of the LPS recognition system [43]. Later Schumann et al. (1990) reported that LBP functions as a carrier protein for LPS in plasma, controlling LPS-dependent responses by forming high-affinity complexes that bind to monocytes and macrophages, which then secrete inflammatory cytokines [44]. Currently, host mechanisms that recognize LPS are known as some of the most sensitive. LBP, a protein with a molecular weight of approximately 60 kDa, is synthesized predominantly in the liver. It possesses opsonic activity, binding to the surface of bacteria and mediating the adhesion to macrophages, with consecutive phagocytosis [45]. However, LBP's significance resides in the ability to enhance the association of LPS with CD14, in order to enable the LPS receptor, Toll-like receptor 4 (TLR4), activating the cell [46,47]. The key role of LBP in LPS-induced activation is evidenced by the markedly reduced LPS responsiveness in LBP-deficient mice [48]. Data shows that LBP is involved in a complex mechanism of immune regulation, which includes both up-regulation and down-regulation of inflammatory processes induced by LPS. LBP has a dual role in Gram-negative sepsis. LBP enhances mononuclear LPS-driven cell activation at low levels, but at higher concentrations, during early immune responses, it inhibits this activation [49]. TLR4 itself does not bind to LPS, it uses CD14 as a cofactor to present LPS to MD-2, which then modulates LPS recognition and interacts with TLR4 [50,51,52]. It can be alternatively stated that CD14 delivers LPS from LBP to the signaling receptor complex MD-2/TLR4. This interaction induces a fast response mediated by the MyD88-dependent signaling, which results in the activation of nuclear factor kappa beta (NF-κB) and MAP kinases, ultimately leading to the transcription of proinflammatory cytokines, including TNFα, IL-1β, and IL-6 [53,54]. TLR4 is internalized and induces a delayed response characterized by the activation of the TBK1–IKKε–IRF3 pathway for the synthesis of IFNβ [55]. This process generates a systemic inflammatory response resulting in tissue inflammation and perturbed homeostasis. Psychological stress increases the expression of TLRs on macrophages and amplifies NF-κB activation induced by LPS, through stimulation of the HPA and sympathetic nervous system (SNS) 8.

LBP transfers LPS to either membrane-bound CD14 (mCD14) or to a circulating, soluble CD14 form (sCD14), in order to create LBP/LPS/CD14 micelles [56]. sCD14 transfers monomeric LPS from LPS–LBP complexes to mCD14, activating the cell, or directly to the MD-2/TLR4 receptor complex on cells that do not express mCD14 [57,58]. Beyond monocytes and macrophages, CD14 was detected in many other cell types, including subsets of dendritic cells [59]. Many publications have recorded the importance of CD14 in LPS response. Haziot et al. (1996) found that CD14-deficient mice were

 doi:10.20944/preprints202508.1326.v1

resistant to lethal LPS administration, whereas control mice did not survive [60]. Serum CD14 levels are considered an indicator of the extent of endotoxin-induced cell activation, making it a potential marker of bacterial translocation. The increase in LBP is relatively slow compared to LPS or other acute phase reactants, making it an indicator of sustained interaction between bacteria and immune cells. Serum LBP levels are significantly increased in sepsis (approximately 46.4 μg/mL), compared with healthy subjects (approximately 5.7 μg/mL) [61].

4. IB Marker Alterations in Depression

In MDD, systemic inflammation is well documented, with elevated plasma levels of proinflammatory cytokines and a shift in the monocyte subsets secreting these mediators. In this context, increased levels of proinflammatory cytokines were positively associated with FABP2, LBP and sCD14 [62,63,64]. Higher LBP and LBP/sCD14 concentrations were also linked to a greater CRP production in depression and marital distress 67. These findings support the pathophysiological pathway in which IB disruption, highlighted by enterocyte damage and bacterial translocation, contributes to monocyte activation and the subsequent inflammatory state in depression. Similarly, the reported association between zonulin and IL-6/ IL-8 in acute stress, reinforces the link between IB damage and immune activation [65].

While intestinal permeability markers are frequently altered in individuals with depression, their correlation is not consistent across studies. There is ample evidence supporting associations between zonulin and mental illness, although findings remain partially inconclusive. In contrast to zonulin, which has shown variable reporting across depression studies, serum FABP2 was almost consistently elevated in depressive individuals 65,66,[66]. A controlled experimental study in healthy male participants showed that serum zonulin levels increased within 10 minutes of acute stress exposure and decreased after 60 minutes. Highly stressed men also reported more abdominal symptoms 68. These results are suggestive of transient stress-induced gut barrier disruption. However, its limited sample size and male-only design restrict the generalizability of the results. Elevated zonulin and FABP levels was also observed by Stevens et al. (2017) in individuals physically asymptomatic for gastrointestinal distress with a depressive or an anxiety disorder. Both correlated with plasma LPS and altered gut microbiome 69. Conversely, in addition to higher FABP2 levels, Ohlsson et al. (2018) reported lower zonulin in patients with MDD or a recent suicide attempt, although inverse correlations with MADRS score did not reach statistical significance for zonulin 66. The inverse relationship between the two biomarkers was reported previously in a study on individuals with HIV, high I-FABP and low zonulin predicting mortality [67]. This discrepancy may stem from the fact that zonulin is a regulatory protein involved in tight junction modulation, rather than a marker of epithelial damage. Its levels are influenced by numerous factors, including circadian rhythm [68]. Moreover, inconsistencies in measurement methods, assay sensitivity and specificity, contribute to its variability. In contrast, FABP2 could offer a more stable indicator of IB dysfunction. While elevated zonulin may suggest increased gut permeability, low levels do not necessarily indicate barrier integrity, highlighting the complexity of its interpretation. Some authors do not recommend one single zonulin measurement for the assessment of IB integrity. They propose the assessment of IgG and IgA antibodies against zonulin and other tight junction proteins, as antibodies were deemed more stable when measured 71. This conflicting data indicates the need for further research about the role of antibodies against tight junctions in patients with depression or inflammatory diseases. Some studies have reported no specific permeability markers alteration in depression. Maget et al. (2021) found no significant differences in serum zonulin levels between euthymic and depressed patients, nor between those taking antipsychotic or antidepressant treatment and patients without medication [69]. Iordache et al. (2022) reported no significant association between FABP2 or zonulin levels and depressive symptoms in individuals with inflammatory bowel disease 36. In patients with depression, after a 28-day trial of probiotics, serum zonulin experienced no significant changes [70]. This data highlights once more the heterogeneity of responses associated with the disorder.

 doi:10.20944/preprints202508.1326.v1

Elevated immunoglobulin levels against LPS have been documented in MDD as early as 2008. Serum IgM and IgA levels against enterobacterial LPS were significantly higher in patients with MDD compared to healthy controls 21,[71]. Increased LPS concentrations in cases comorbid with depression were also identified in tissue samples from the oral cavity of patients with chronic apical periodontitis. Moreover, LPS levels showed positive associations with the severity of depression [72]. This finding is relevant because it supports the hypothesis that peripheral sources of inflammation, even originating outside the gut, may contribute to the pathophysiology of depression. Hostile marital interactions were associated with elevated LBP and higher LBP/sCD14 in individuals, especially in those with a mood disorder history 67. Unlike transient permeability markers such as LPS, elevated LBP levels reflect chronic exposure to bacterial endotoxins. In depression, where prolonged immune activation is frequently observed, this characteristic is extremely relevant. Ohlsson et al. (2018) found positive correlations between sCD14 and I-FABP in patients with depression and a recent suicidal behavior, but no significant differences between depressed patients and controls in sCD14 66. sCD14 is indicative of monocyte activation but is not necessarily linked to compromised gut integrity. This could explain the limited alterations in depressed patients [73].

Antidepressive treatment such as selective serotonin reuptake inhibitors (SSRI) Paroxetine, tricyclic antidepressants Clomipramine and Amitriptyline and monoamine oxidase inhibitors (MAOI) Tranylcypromine can prevent LPS-generated microglial changes, microglial oxidative stress markers, or the production of inflammatory markers [74]. This data indicates that antidepressants might also act by altering the microglial phenotype, reducing neuroinflammation. Patients with higher baseline levels of I-FABP had better clinical outcomes after 6 weeks of SSRI treatment, as measured by the decrease in their depression score on the 24-item Hamilton Depression Rating Scale (dHDRS24) [75]. This may also suggest that individuals with greater IB damage respond better to treatments targeting gut-related inflammation. However, this interpretation should be approached with caution, as current evidence remains limited and further validation is needed.

Intestinal permeability markers are also frequently altered in conditions associated with depression, such as chronic immune-mediated inflammatory diseases (IMIDs), as well as in HIV and metabolic syndrome-related disorders. This is possibly due to the combined effects of sustained activation of immune pathways and chronic inflammation, alongside the psychological burden of the illness. Therefore, evaluating intestinal permeability markers in these disorders is important, as they may provide insight into shared inflammatory mechanisms contributing to depressive symptoms. Increased zonulin levels have been reported in individuals with ankylosing spondylitis and inflammatory bowel disease (IBS) [76,77]. A positive correlation between depressive symptoms and LBP was also highlighted in patients with IBS 36. Zonulin dysfunction and elevated LPS levels were also repeatedly linked to conditions such as diabetes, obesity or cardiovascular disease [78,79,80,81]. Administration of *Bifidobacterium* supplements, together with a dietary fiber, to obese or overweight participants, resulted in changes in zonulin that significantly correlated with changes in trunk fat mass [82] LBP is linked to old age, obesity and metabolic syndrome, while sCD14 correlates with age but not with metabolic markers [83,84]. This lack of correlation may be due to the fact that sCD14 acts as a general marker of monocyte activation, influenced more by age-related immune changes than by metabolic dysregulation. FABP2 was linked to Type 1 Diabetes triggers, and, moreover, FABP2 gene variants may increase Type 2 Diabetes risk [85,86]. In patients with heart failure, I-FABP is associated with disease severity and low intestinal microbe diversity [87]. Probiotics and Inulin combination ameliorated chronic inflammation and endotoxemia, as well as depression and anxiety levels in coronary artery disease patients [88]. Moderate to severe COVID-19 has been associated with lower levels of FABP2 in the bloodstream. As a result, FABP2 was proposed as a marker of infected enterocyte functional modifications [89]. COVID-19 is also a condition associated with higher rates of depression, possibly as a result of neuroinflammation and neurological complications, alongside social isolation and economic hardship [90]. Comparable to findings in other somatic disorders, the association between depression and COVID-19 may involve similar changes through shared inflammatory GBA mechanisms, driven by increased gut permeability.

 doi:10.20944/preprints202508.1326.v1

5. Conclusions

Numerous studies highlight the role of intestinal permeability in stress and depression, though much remains to be understood. Prior research faced difficulties reaching clear conclusions due to differences in study design, variation in biomarkers, and the absence of standardized tests. In this review, only two databases (PubMed and Embase) were consulted, potentially introducing selection bias and overlooking relevant studies. The focus was also restricted to a limited number of blood-based markers, excluding stool or saliva biomarkers, and other emerging indicators of gut permeability. Included studies varied in methodology, biomarker assays, and population characteristics, limiting comparability. Confounding factors such as diet, medication use, and comorbidities were often insufficiently controlled. Nevertheless, reported alterations in IB permeability and immune activation markers suggest a potential role for bacterial translocation and low-grade systemic inflammation as mediating factors in the pathophysiology of depression. Investigating IB permeability beyond gastrointestinal conditions is a growing field. However, translating these findings into evidence-based applications has not been fully accomplished. Modulating the gut microbiota and IB permeability signifies a novel therapeutic approach for mental disorders. Future studies are needed to clarify mechanistic pathways, establish valid biomarkers, and optimize microbiota-based therapies. Overcoming such problems will be essential for the development of effective psychiatric care, supporting a more holistic approach to mental health.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Table 1. Blood-Based Markers of Intestinal Permeability and Their Clinical Significance in the Context of Depression

Author Contributions: Conceptualization, Anca C. Bibolar; Methodology, Anca C. Bibolar, Ramona L. Păunescu, Bianca D. Crecan-Suciu; Validation, Anca C. Bibolar, Vlad I. Nechita; Formal Analysis, Anca C. Bibolar, Vlad I. Nechita; Investigation, Anca C. Bibolar, Vlad I. Nechita; Writing – Original Draft Preparation, Anca C. Bibolar, Vlad I. Nechita; Writing – Review & Editing, Anca C. Bibolar, Vlad I. Nechita, Ramona L. Păunescu, Bianca D. Crecan-Suciu, Olivia Verisezan-Roșu; Visualization, Anca C. Bibolar, Olivia Verisezan-Roșu; Supervision, Ioana V. Micluția; Project Administration, Anca C. Bibolar, Ioana V. Micluția; Funding Acquisition, not applicable.All authors have read and agreed to the published version of the manuscript.

Funding: No funding was received for conducting this study.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: During the preparation of this manuscript, the authors used ChatGPT-4 (OpenAI, 2025) for language assistance and to aid in the generation and formatting of Table 1. The authors have reviewed and edited all outputs and assume full responsibility for the final version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Key Points: Intestinal barrier dysfunction may contribute to the pathophysiology of depression through microbial translocation and low-grade systemic inflammation.nBlood-based biomarkers of intestinal permeability such as zonulin, I-FABP, LPS, LBP, and sCD14 have shown altered levels in patients with depression, although findings remain inconsistent. Zonulin and FABP2 represent distinct dimensions of IB impairment, with FABP2 more consistently elevated across studies. LPS-induced neuroinflammation and BBB disruption support its role in inflammation-driven depressive

 doi:10.20944/preprints202508.1326.v1

phenotypes. Despite their potential, intestinal permeability biomarkers are not yet validated for clinical application in psychiatric practice.

References:

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, Meaney MJ, Nestler EJ. Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018 Jan;84:272-288. doi: 10.1016/j.neubiorev.2017.08.019. Epub 2017 Aug 30. PMID: 28859997; PMCID: PMC5729118.
2. Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. J Endocr Soc. 2020 Feb 20;4(2):bvz039. doi: 10.1210/jendso/bvz039. PMID: 32099951; PMCID: PMC7033038.
3. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21. doi: 10.1038/nrgastro.2016.169. Epub 2016 Nov 16. PMID: 27848962; PMCID: PMC5554468.
4. Rudzki L, Maes M. The Microbiota-Gut-Immune-Glia (MGIG) Axis in Major Depression. Mol Neurobiol. 2020 Oct;57(10):4269-4295. doi: 10.1007/s12035-020-01961-y. Epub 2020 Jul 22. PMID: 32700250.
5. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024 Mar;19(2):275-293. doi: 10.1007/s11739-023-03374-w. Epub 2023 Jul 28. PMID: 37505311; PMCID: PMC10954893.
6. Kowalski K, Mulak A. Brain-Gut-Microbiota Axis in Alzheimer's Disease. J Neurogastroenterol Motil. 2019 Jan 31;25(1):48-60. doi: 10.5056/jnm18087. PMID: 30646475; PMCID: PMC6326209.
7. Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLOS ONE, 6(12), e28032. https://doi.org/10.1371/journal.pone.0028032
8. Denman CR, Park SM, Jo J. Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer's and Parkinson's disease. Front Neurosci. 2023 Nov 13;17:1268419. doi: 10.3389/fnins.2023.1268419. PMID: 38075261; PMCID: PMC10704039.
9. Behairi N, Belkhelfa M, Rafa H, Labsi M, Deghbar N, Bouzid N, Mesbah-Amroun H, Touil-Boukoffa C. All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats. J Neuroimmunol. 2016 Nov 15;300:21-29. doi: 10.1016/j.jneuroim.2016.10.004. Epub 2016 Oct 8. PMID: 27806872.
10. de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, Bravaccio C. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):418-24. doi: 10.1097/MPG.0b013e3181dcc4a5. PMID: 20683204.
11. Ishida I, Ogura J, Aizawa E, Ota M, Hidese S, Yomogida Y, Matsuo J, Yoshida S, Kunugi H. Gut permeability and its clinical relevance in schizophrenia. Neuropsychopharmacol Rep. 2022 Mar;42(1):70-76. doi: 10.1002/npr2.12227. Epub 2022 Jan 25. PMID: 35080340; PMCID: PMC8919127.
12. Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med. 1997 May 5;185(9):1661-70. doi: 10.1084/jem.185.9.1661. PMID: 9151903; PMCID: PMC2196288.
13. Yin R, Zhang K, Li Y, Tang Z, Zheng R, Ma Y, Chen Z, Lei N, Xiong L, Guo P, Li G, Xie Y. Lipopolysaccharide-induced depression-like model in mice: meta-analysis and systematic evaluation. Front Immunol. 2023 Jun 8;14:1181973. doi: 10.3389/fimmu.2023.1181973. PMID: 37359525; PMCID: PMC10285697.

 doi:10.20944/preprints202508.1326.v1

14. Peng X, Luo Z, He S, Zhang L, Li Y. Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy. Front Cell Infect Microbiol. 2021 Nov 4;11:768108. doi: 10.3389/fcimb.2021.768108. PMID: 34804998; PMCID: PMC8599158.
15. Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb Cell. 2019 Sep 27;6(10):454-481. doi: 10.15698/mic2019.10.693. PMID: 31646148; PMCID: PMC6780009.
16. Zhao X, Cao F, Liu Q, Li X, Xu G, Liu G, Zhang Y, Yang X, Yi S, Xu F, Fan K, Ma J. Behavioral, inflammatory and neurochemical disturbances in LPS and UCMS-induced mouse models of depression. Behav Brain Res. 2019 May 17;364:494-502. doi: 10.1016/j.bbr.2017.05.064. Epub 2017 May 29. Erratum in: Behav Brain Res. 2023 Aug 24;452:114573. doi: 10.1016/j.bbr.2023.114573. PMID: 28572058.
17. Maes, M., Kubera, M., Leunis, J.-C., Berk, M., Geffard, M., & Bosmans, E. (2012). In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica, 127(5), 344–354. doi:10.1111/j.1600-0447.2012.01908.x
18. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019 Aug;68(8):1516-1526. doi: 10.1136/gutjnl-2019-318427. Epub 2019 May 10. PMID: 31076401; PMCID: PMC6790068.
19. Seethaler B, Basrai M, Neyrinck AM, Nazare JA, Walter J, Delzenne NM, Bischoff SC. Biomarkers for assessment of intestinal permeability in clinical practice. Am J Physiol Gastrointest Liver Physiol. 2021 Jul 1;321(1):G11-G17. doi: 10.1152/ajpgi.00113.2021. Epub 2021 May 19. PMID: 34009040.
20. Safadi JM, Quinton AMG, Lennox BR, Burnet PWJ, Minichino A. Gut dysbiosis in severe mental illness and chronic fatigue: a novel trans-diagnostic construct? A systematic review and meta-analysis. Mol Psychiatry. 2022 Jan;27(1):141-153. doi: 10.1038/s41380-021-01032-1. Epub 2021 Feb 8. PMID: 33558650; PMCID: PMC8960409.
21. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, Antalis TM, Vogel SN, Zhao A, Yang S, Arrietta MC, Meddings JB, Fasano A. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16799-804. doi: 10.1073/pnas.0906773106. Epub 2009 Sep 15. PMID: 19805376; PMCID: PMC2744629.
22. Fasano, A., Not, T., Wang, W., Uzzau, S., Berti, I., Tommasini, A., & Goldblum, S. E. (2000). Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. The Lancet, 355(9214), 1518–1519. doi:10.1016/s0140-6736(00)02169-3
23. Fasano, A. (2011). Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. Physiological Reviews, 91(1), 151–175. doi:10.1152/physrev.00003.2008
24. Veres-Székely A, Szász C, Pap D, Szebeni B, Bokrossy P, Vannay Á. Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. Int J Mol Sci. 2023 Apr 19;24(8):7548. doi: 10.3390/ijms24087548. PMID: 37108711; PMCID: PMC10139156.
25. Malíčková K, Francová I, Lukáš M, Kolář M, Králíková E, Bortlík M, Ďuricová D, Štěpánková L, Zvolská K, Pánková A, Zima T. Fecal zonulin is elevated in Crohn's disease and in cigarette smokers. Pract Lab Med. 2017 Sep 23;9:39-44. doi: 10.1016/j.plabm.2017.09.001. PMID: 29034305; PMCID: PMC5633835.
26. R.K. Ockner, J.A. Manning, R.B. Poppenhausen, W.K. Ho, A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues, Science 177 Ž . 1972 56–58
27. Zimmerman, A. W., & Veerkamp, J. H. (2002). New insights into the structure and function of fatty acid-binding proteins. Cellular and Molecular Life Sciences (CMLS), 59(7), 1096–1116. doi:10.1007/s00018-002-8490-y
28. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008 Jun;7(6):489-503. doi: 10.1038/nrd2589. PMID: 18511927; PMCID: PMC2821027.
29. Adriaanse, M. P. M., Tack, G. J., Passos, V. L., Damoiseaux, J. G. M. C., Schreurs, M. W. J., van Wijck, K., … Vreugdenhil, A. C. E. (2013). Serum I-FABP as marker for enterocyte damage in coeliac disease and its

 doi:10.20944/preprints202508.1326.v1

relation to villous atrophy and circulating autoantibodies. Alimentary Pharmacology & Therapeutics, 37(4), 482–490. doi:10.1111/apt.12194

30. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, Glatz JF. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem. 2003 Oct;36(7):529-35. doi: 10.1016/s0009-9120(03)00096-1. PMID: 14563446.
31. Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One. 2013 Nov 20;8(11):e81318. doi: 10.1371/journal.pone.0081318. PMID: 24278421; PMCID: PMC3835575.
32. Iordache MM, Tocia C, Aschie M, Dumitru A, Manea M, Cozaru GC, Petcu L, Vlad SE, Dumitru E, Chisoi A. Intestinal Permeability and Depression in Patients with Inflammatory Bowel Disease. J Clin Med. 2022 Aug 30;11(17):5121. doi: 10.3390/jcm11175121. PMID: 36079050; PMCID: PMC9457405.
33. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu Rev Biochem 71:635–700.
34. Needham BD, Trent MS. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. Nat Rev Microbiol. 2013 Jul;11(7):467-81. doi: 10.1038/nrmicro3047. Epub 2013 Jun 10. PMID: 23748343; PMCID: PMC6913092.
35. Li Y, Shi Z, Radauer-Preiml I, Andosch A, Casals E, Luetz-Meindl U, Cobaleda M, Lin Z, Jaberi-Douraki M, Italiani P, Horejs-Hoeck J, Himly M, Monteiro-Riviere NA, Duschl A, Puntes VF, Boraschi D. Bacterial endotoxin (lipopolysaccharide) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation. Nanotoxicology. 2017 Nov-Dec;11(9-10):1157-1175.
36. Westphal O, Luderitz O, Bister E. Uber die extraction von bacterien mit phenol/wasser. Z Naturforsch Teil B 1952; 7: 148.
37. Bahador M, Cross AS. From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J Endotoxin Res. 2007;13(5):251-79. doi: 10.1177/0968051907085986. PMID: 17986486.
38. Lowry SF. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 2005; 24 (Suppl. 1): 94–100.
39. Bossù P, Cutuli D, Palladino I, Caporali P, Angelucci F, Laricchiuta D, Gelfo F, De Bartolo P, Caltagirone C, Petrosini L. A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18. J Neuroinflammation. 2012 May 29;9:101. doi: 10.1186/1742-2094-9-101. PMID: 22642744; PMCID: PMC3444884.
40. Jiang W, Luo Z, Stephenson S, Li H, Di Germanio C, Norris PJ, Fuchs D, Zetterberg H, Gisslen M, Price RW. Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. J Infect Dis. 2021 May 20;223(9):1612-1620. doi: 10.1093/infdis/jiaa765. PMID: 33320240; PMCID: PMC8136977.
41. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 2004 Dec;6(15):1361-7. doi: 10.1016/j.micinf.2004.08.015. PMID: 15596121.
42. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986 Sep 1;164(3):777-93. doi: 10.1084/jem.164.3.777. PMID: 2427635; PMCID: PMC2188379.
43. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science. 1990 Sep 21;249(4975):1429-31. doi: 10.1126/science.2402637. PMID: 2402637.
44. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med. 1989 Oct 1;170(4):1231-41. doi: 10.1084/jem.170.4.1231. PMID: 2477488; PMCID: PMC2189482.
45. Wright, S., Ramos, R., Tobias, P., Ulevitch, R., & Mathison, J. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 249(4975), 1431–1433. doi:10.1126/science.1698311

46. Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., & Gusovsky, F. (1999). Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction. Journal of Biological Chemistry, 274(16), 10689–10692. doi:10.1074/jbc.274.16.10689

10.1074/jbc.274.16.10689

47. Wurfel M M, Monks B G, Ingalls R R, Dedrick R L, Delude R, Zhou D, Lamping N, Schumann R R, Thieringer R, Fenton M J, Wright S D, Golenbock D. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997;186:2051–2056. doi: 10.1084/jem.186.12.2051.
48. Gutsmann T, Müller M, Carroll SF, MacKenzie RC, Wiese A, et al. (2001) Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 69: 6942–6950.
49. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007 Sep 7;130(5):906-17. doi: 10.1016/j.cell.2007.08.002. PMID: 17803912.
50. Ohto U, Fukase K, Miyake K, Satow Y . Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316: 1632–1634.
51. Jagtap P, Prasad P, Pateria A, Deshmukh SD, Gupta S. A Single Step in vitro Bioassay Mimicking TLR4-LPS Pathway and the Role of MD2 and CD14 Coreceptors. Front Immunol. 2020 Jan 24;11:5. doi: 10.3389/fimmu.2020.00005. PMID: 32038655; PMCID: PMC6992608.
52. Kagan, J. C., & Medzhitov, R. (2006). Phosphoinositide-Mediated Adaptor Recruitment Controls Toll-like Receptor Signaling. Cell, 125(5), 943–955. doi:10.1016/j.cell.2006.03.047
53. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006 May;13(5):816-25. doi: 10.1038/sj.cdd.4401850. PMID: 16410796.
54. Tsukamoto, H., Takeuchi, S., Kubota, K., Kobayashi, Y., Kozakai, S., Ukai, I., … Tomioka, Y. (2018). Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1–IKKϵ–IRF3 axis activation. Journal of Biological Chemistry, 293(26), 10186–10201. doi:10.1074/jbc.m117.796631
55. Haziot A, et al. , The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol, 1988. 141(2): p. 547–52.
56. Frey, E. A. (1992). Soluble CD14 participates in the response of cells to lipopolysaccharide. Journal of Experimental Medicine, 176(6), 1665–1671. doi:10.1084/jem.176.6.1665
57. Kitchens, R. L., & Thompson, P. A. (2005). Modulatory effects of sCD14 and LBP on LPS-host cell interactions. Journal of Endotoxin Research, 11(4), 225–229. doi:10.1177/09680519050110040701
58. Mahnke K, Becher E, Ricciardi-Castagnoli P, Luger TA, Schwarz T, Grabbe S. CD14 is expressed by subsets of murine dendritic cells and upregulated by lipopolysaccharide. Adv Exp Med Biol. 1997;417:145-59. doi: 10.1007/978-1-4757-9966-8_25. PMID: 9286353.
59. Haziot A, Ferrero E, Köntgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity. 1996 Apr;4(4):407-14. doi: 10.1016/s1074-7613(00)80254-x. PMID: 8612135.
60. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis. 2003 Jan 15;187(2):287-91. doi: 10.1086/346046. Epub 2002 Dec 19. PMID: 12552453.
61. Alvarez-Mon MA, Gómez AM, Orozco A, Lahera G, Sosa MD, Diaz D et al. Abnormal Distribution and Function of Circulating Monocytes and Enhanced Bacterial Translocation in Major Depressive Disorder. Front Psychiatry. 2019 Nov 15;10:812. doi: 10.3389/fpsyt.2019.00812. PMID: 31803077; PMCID: PMC6873610.
62. Ohlsson L, Gustafsson A, Lavant E, Suneson K, Brundin L, Westrin A et al. Leaky gut biomarkers in depression and suicidal behavior. Acta Psychiatr Scand. 2019;139(2):185-193. doi: 10.1111/acps.12978.
63. Kiecolt-Glaser JK, Wilson SJ, Bailey ML, Andridge R, Peng J, Jaremka LM et al. Marital distress, depression, and a leaky gut: Translocation of bacterial endotoxin as a pathway to inflammation.

 doi:10.20944/preprints202508.1326.v1

Psychoneuroendocrinology. 2018 Dec;98:52-60. doi: 10.1016/j.psyneuen.2018.08.007. Epub 2018 Aug 4. PMID: 30098513; PMCID: PMC6260591.

64. Linninge, C., Jönsson, P., Bolinsson, H., Önning, G., Eriksson, J., Johansson, G., & Ahrné, S. (2018). Effects of acute stress provocation on cortisol levels, zonulin and inflammatory markers in low- and high-stressed men. Biological Psychology. doi:10.1016/j.biopsycho.2018.08.0
65. Stevens BR, Goel R, Seungbum K, Richards EM, Holbert RC, Pepine CJ et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut. 2018;67(8):1555-1557. doi: 10.1136/gutjnl-2017-314759.
66. Hunt, P. W., Sinclair, E., Rodriguez, B., Shive, C., Clagett, B., Funderburg, N., … Lederman, M. M. (2014). Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. The Journal of Infectious Diseases, 210(8), 1228–1238. doi:10.1093/infdis/jiu238
67. Vojdani A, Vojdani E, Kharrazian D. Fluctuation of zonulin levels in blood vs stability of antibodies. World J Gastroenterol. 2017 Aug 21;23(31):5669-5679. doi: 10.3748/wjg.v23.i31.5669. PMID: 28883692; PMCID: PMC5569281.
68. Maget A, Dalkner N, Hamm C, Bengesser SA, Fellendorf FT, Platzer Mmet al. Sex differences in zonulin in affective disorders and associations with current mood symptoms. J Affect Disord. 2021;294:441–446. doi: 10.1016/j.jad.2021.07.021.
69. Reininghaus, E. Z., Platzer, M., Kohlhammer-Dohr, A., Hamm, C., Mörkl, S., Bengesser, S. A., … Dalkner, N. (2020). PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial. Nutrients, 12(11), 3422. doi:10.3390/nu12113422
70. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117-24. PMID: 18283240.
71. Gomes C, Martinho FC, Barbosa DS, Antunes LS, Póvoa HCC, Baltus THL, Morelli NR, Vargas HO, Nunes SOV, Anderson G, Maes M. Increased Root Canal Endotoxin Levels are Associated with Chronic Apical Periodontitis, Increased Oxidative and Nitrosative Stress, Major Depression, Severity of Depression, and a Lowered Quality of Life. Mol Neurobiol. 2018 Apr;55(4):2814-2827. doi: 10.1007/s12035-017-0545-z. Epub 2017 Apr 28. PMID: 28455694.
72. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS 2015;29:1263–1265.
73. Mariani N, Everson J, Pariante CM, Borsini A. Modulation of microglial activation by antidepressants. J Psychopharmacol. 2022 Feb;36(2):131-150. doi: 10.1177/02698811211069110. Epub 2022 Jan 29. PMID: 35098788; PMCID: PMC8847767.
74. Liśkiewicz, P., Kaczmarczyk, M., Misiak, B., Wroński, M., Bąba-Kubiś, A., Skonieczna-Żydecka, K., … Samochowiec, J. (2020). Analysis of gut microbiota and intestinal integrity markers of inpatients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 110076. doi:10.1016/j.pnpbp.2020.110076
75. Ciccia, F., Guggino, G., Rizzo, A., Alessandro, R., Luchetti, M. M., Milling, S., … Triolo, G. (2017). Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 76(6), 1123–1132. doi:10.1136/annrheumdis-2016-210000
76. Wang X, Memon AA, Palmér K, Hedelius A, Sundquist J, Sundquist K. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol. 2022 Jan 3;22(1):3. doi: 10.1186/s12876-021-02075-y. PMID: 34979917; PMCID: PMC8725386.
77. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Cartenì M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006 May;55(5):1443-9. doi: 10.2337/db05-1593. PMID: 16644703.
78. Ohlsson B, Orho-Melander M, Nilsson PM. Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease

Manifestations. Int J Mol Sci. 2017 Mar 8;18(3):582. doi: 10.3390/ijms18030582. PMID: 28282855; PMCID: PMC5372598.

79. Ahmad F, Karim A, Khan J, Qaisar R. Plasma zonulin correlates with cardiac dysfunction and poor physical performance in patients with chronic heart failure. Life Sci. 2022 Dec 15;311(Pt A):121150. doi: 10.1016/j.lfs.2022.121150. Epub 2022 Nov 3. PMID: 36336128.
80. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, et al. (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292: E740–E747
81. Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lähdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial. EBioMedicine. 2016 Nov;13:190-200. doi: 10.1016/j.ebiom.2016.10.036. Epub 2016 Oct 26. PMID: 27810310; PMCID: PMC5264483.
82. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One. 2013;8(1):e54600. doi: 10.1371/journal.pone.0054600. Epub 2013 Jan 22. PMID: 23349936; PMCID: PMC3551812.
83. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, et al. (2007) Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 17: 1374–1380.
84. Harms RZ, Ostlund KR, Cabrera MS, Edwards E, Fisher M, Sarvetnick N. Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes. Front Immunol. 2020 Sep 15;11:1922. doi: 10.3389/fimmu.2020.01922. PMID: 33042112; PMCID: PMC7523316.
85. Qiu CJ, Ye XZ, Yu XJ, Peng XR, Li TH. Association between FABP2 Ala54Thr polymorphisms and type 2 diabetes mellitus risk: a HuGE Review and Meta-Analysis. J Cell Mol Med. 2014 Dec;18(12):2530-5. doi: 10.1111/jcmm.12385. Epub 2014 Nov 11. PMID: 25388378; PMCID: PMC4302657.
86. Nendl A, Raju SC, Broch K, Mayerhofer CCK, Holm K, Halvorsen B, Lappegård KT, Moscavitch S, Hov JR, Seljeflot I, Trøseid M, Awoyemi A. Intestinal fatty acid binding protein is associated with cardiac function and gut dysbiosis in chronic heart failure. Front Cardiovasc Med. 2023 Jun 2;10:1160030. doi: 10.3389/fcvm.2023.1160030. PMID: 37332580; PMCID: PMC10272617.
87. Moludi, J., Khedmatgozar, H., Nachvak, S. M., Abdollahzad, H., Moradinazar, M., & Sadeghpour tabaei, A. (2021). The effects of co-administration of probiotics and prebiotics on chronic inflammation, and depression symptoms in patients with coronary artery diseases: a randomized clinical trial. Nutritional Neuroscience, 1–10. doi:10.1080/1028415x.2021.1889451
88. Assante G, Tourna A, Carpani R, Ferrari F, Prati D, Peyvandi F, Blasi F, Bandera A, Le Guennec A, Chokshi S, Patel VC, Cox IJ, Valenti L, Youngson NA. Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death. Sci Rep. 2022 Nov 5;12(1):18792. doi: 10.1038/s41598-022-23282-x. PMID: 36335131; PMCID: PMC9637119.
89. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 May;8(5):416-427. doi: 10.1016/S2215-0366(21)00084-5. Epub 2021 Apr 6. PMID: 33836148; PMCID: PMC8023694.